Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 135 entries
Sorted by: Best Match Show Resources per page
Acute psychological stress-induced water intoxication.

International journal of psychiatry in clinical practice

Mukherjee S, Antonarakis ES, Asaduzzaman S, Peters JR.
PMID: 24930797
Int J Psychiatry Clin Pract. 2005;9(2):142-4. doi: 10.1080/13651500510028986.

Excessive water drinking is a recognised feature of schizophrenia. We present here a case of excessive water drinking precipitated by acute psychological stress. A 52-year-old woman, with no previous mental health problems, was found in a state of altered...

Cite
Mukherjee S, Antonarakis ES, Asaduzzaman S, et al. Acute psychological stress-induced water intoxication. Int J Psychiatry Clin Pract. 2005;9(2):142-4doi: 10.1080/13651500510028986.
Mukherjee, S., Antonarakis, E. S., Asaduzzaman, S., & Peters, J. R. (2005). Acute psychological stress-induced water intoxication. International journal of psychiatry in clinical practice, 9(2), 142-4. https://doi.org/10.1080/13651500510028986
Mukherjee, Sagarika, et al. "Acute psychological stress-induced water intoxication." International journal of psychiatry in clinical practice vol. 9,2 (2005): 142-4. doi: https://doi.org/10.1080/13651500510028986
Mukherjee S, Antonarakis ES, Asaduzzaman S, Peters JR. Acute psychological stress-induced water intoxication. Int J Psychiatry Clin Pract. 2005;9(2):142-4. doi: 10.1080/13651500510028986. PMID: 24930797.
Copy Download .nbib Format: NLM
Molecular heterogeneity of localized prostate cancer: more different than alike.

Translational cancer research

Tosoian JJ, Antonarakis ES.
PMID: 28529909
Transl Cancer Res. 2017 Feb;6:S47-S50. doi: 10.21037/tcr.2017.02.17.

No abstract available.

Cite
Tosoian JJ, Antonarakis ES. Molecular heterogeneity of localized prostate cancer: more different than alike. Transl Cancer Res. 2017;6:S47-S50doi: 10.21037/tcr.2017.02.17.
Tosoian, J. J., & Antonarakis, E. S. (2017). Molecular heterogeneity of localized prostate cancer: more different than alike. Translational cancer research, 6S47-S50. https://doi.org/10.21037/tcr.2017.02.17
Tosoian, Jeffrey J, and Antonarakis, Emmanuel S. "Molecular heterogeneity of localized prostate cancer: more different than alike." Translational cancer research vol. 6 (2017): S47-S50. doi: https://doi.org/10.21037/tcr.2017.02.17
Tosoian JJ, Antonarakis ES. Molecular heterogeneity of localized prostate cancer: more different than alike. Transl Cancer Res. 2017 Feb;6:S47-S50. doi: 10.21037/tcr.2017.02.17. PMID: 28529909; PMCID: PMC5438201.
Copy Download .nbib Format: NLM
Enzalutamide: The emperor of all anti-androgens.

Translational andrology and urology

Antonarakis ES.
PMID: 24076589
Transl Androl Urol. 2013 Jun;2(2):119-120. doi: 10.3978/j.issn.2223-4683.2012.09.04.

No abstract available.

Cite
Antonarakis ES. Enzalutamide: The emperor of all anti-androgens. Transl Androl Urol. 2013;2(2):119-120doi: 10.3978/j.issn.2223-4683.2012.09.04.
Antonarakis, E. S. (2013). Enzalutamide: The emperor of all anti-androgens. Translational andrology and urology, 2(2), 119-120. https://doi.org/10.3978/j.issn.2223-4683.2012.09.04
Antonarakis, Emmanuel S. "Enzalutamide: The emperor of all anti-androgens." Translational andrology and urology vol. 2,2 (2013): 119-120. doi: https://doi.org/10.3978/j.issn.2223-4683.2012.09.04
Antonarakis ES. Enzalutamide: The emperor of all anti-androgens. Transl Androl Urol. 2013 Jun;2(2):119-120. doi: 10.3978/j.issn.2223-4683.2012.09.04. PMID: 24076589; PMCID: PMC3785324.
Copy Download .nbib Format: NLM
Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.

Translational andrology and urology

Sedhom R, Antonarakis ES.
PMID: 31392164
Transl Androl Urol. 2019 Jul;8:S341-S345. doi: 10.21037/tau.2019.05.02.

No abstract available.

Cite
Sedhom R, Antonarakis ES. Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale. Transl Androl Urol. 2019;8:S341-S345doi: 10.21037/tau.2019.05.02.
Sedhom, R., & Antonarakis, E. S. (2019). Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale. Translational andrology and urology, 8S341-S345. https://doi.org/10.21037/tau.2019.05.02
Sedhom, Ramy, and Antonarakis, Emmanuel S. "Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale." Translational andrology and urology vol. 8 (2019): S341-S345. doi: https://doi.org/10.21037/tau.2019.05.02
Sedhom R, Antonarakis ES. Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale. Transl Androl Urol. 2019 Jul;8:S341-S345. doi: 10.21037/tau.2019.05.02. PMID: 31392164; PMCID: PMC6642951.
Copy Download .nbib Format: NLM
The effect of financial crises on air pollutant emissions: An assessment of the short vs. medium-term effects.

The Science of the total environment

Pacca L, Antonarakis A, Schröder P, Antoniades A.
PMID: 31518780
Sci Total Environ. 2020 Jan 01;698:133614. doi: 10.1016/j.scitotenv.2019.133614. Epub 2019 Aug 07.

This paper empirically investigates the impact of financial crises on air pollutant emissions (CO

Cite
Pacca L, Antonarakis A, Schröder P, et al. The effect of financial crises on air pollutant emissions: An assessment of the short vs. medium-term effects. Sci Total Environ. 2019;698:133614doi: 10.1016/j.scitotenv.2019.133614.
Pacca, L., Antonarakis, A., Schröder, P., & Antoniades, A. (2020). The effect of financial crises on air pollutant emissions: An assessment of the short vs. medium-term effects. The Science of the total environment, 698133614. https://doi.org/10.1016/j.scitotenv.2019.133614
Pacca, Lucia, et al. "The effect of financial crises on air pollutant emissions: An assessment of the short vs. medium-term effects." The Science of the total environment vol. 698 (2020): 133614. doi: https://doi.org/10.1016/j.scitotenv.2019.133614
Pacca L, Antonarakis A, Schröder P, Antoniades A. The effect of financial crises on air pollutant emissions: An assessment of the short vs. medium-term effects. Sci Total Environ. 2020 Jan 01;698:133614. doi: 10.1016/j.scitotenv.2019.133614. Epub 2019 Aug 07. PMID: 31518780.
Copy Download .nbib Format: NLM
AR-V7 and treatment selection in advanced prostate cancer: are we there yet?.

Precision cancer medicine

Bastos DA, Antonarakis ES.
PMID: 30370427
Precis Cancer Med. 2018 Sep;1. doi: 10.21037/pcm.2018.09.01. Epub 2018 Sep 18.

No abstract available.

Cite
Bastos DA, Antonarakis ES. AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. Precis Cancer Med. 2018;1doi: 10.21037/pcm.2018.09.01.
Bastos, D. A., & Antonarakis, E. S. (2018). AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. Precision cancer medicine, 1. https://doi.org/10.21037/pcm.2018.09.01
Bastos, Diogo A, and Antonarakis, Emmanuel S. "AR-V7 and treatment selection in advanced prostate cancer: are we there yet?." Precision cancer medicine vol. 1 (2018). doi: https://doi.org/10.21037/pcm.2018.09.01
Bastos DA, Antonarakis ES. AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. Precis Cancer Med. 2018 Sep;1. doi: 10.21037/pcm.2018.09.01. Epub 2018 Sep 18. PMID: 30370427; PMCID: PMC6201248.
Copy Download .nbib Format: NLM
AR Signaling in Human Malignancies: Prostate Cancer and Beyond.

Cancers

Antonarakis ES.
PMID: 29346310
Cancers (Basel). 2018 Jan 18;10(1). doi: 10.3390/cancers10010022.

The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This...

Cite
Antonarakis ES. AR Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel). 2018;10(1)doi: 10.3390/cancers10010022.
Antonarakis, E. S. (2018). AR Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers, 10(1), . https://doi.org/10.3390/cancers10010022
Antonarakis, Emmanuel S. "AR Signaling in Human Malignancies: Prostate Cancer and Beyond." Cancers vol. 10,1 (2018). doi: https://doi.org/10.3390/cancers10010022
Antonarakis ES. AR Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel). 2018 Jan 18;10(1). doi: 10.3390/cancers10010022. PMID: 29346310; PMCID: PMC5789372.
Copy Download .nbib Format: NLM
Down syndrome.

Nature reviews. Disease primers

Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, Sherman SL, Reeves RH.
PMID: 32029743
Nat Rev Dis Primers. 2020 Feb 06;6(1):9. doi: 10.1038/s41572-019-0143-7.

Trisomy 21, the presence of a supernumerary chromosome 21, results in a collection of clinical features commonly known as Down syndrome (DS). DS is among the most genetically complex of the conditions that are compatible with human survival post-term,...

Cite
Antonarakis SE, Skotko BG, Rafii MS, et al. Down syndrome. Nat Rev Dis Primers. 2020;6(1):9doi: 10.1038/s41572-019-0143-7.
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020). Down syndrome. Nature reviews. Disease primers, 6(1), 9. https://doi.org/10.1038/s41572-019-0143-7
Antonarakis, Stylianos E, et al. "Down syndrome." Nature reviews. Disease primers vol. 6,1 (2020): 9. doi: https://doi.org/10.1038/s41572-019-0143-7
Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, Sherman SL, Reeves RH. Down syndrome. Nat Rev Dis Primers. 2020 Feb 06;6(1):9. doi: 10.1038/s41572-019-0143-7. PMID: 32029743; PMCID: PMC8428796.
Copy Download .nbib Format: NLM
Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.

JCO precision oncology

Markowski MC, Silberstein JL, Eshleman JR, Eisenberger MA, Luo J, Antonarakis ES.
PMID: 29170762
JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00127. Epub 2017 Oct 30.

PURPOSE: A splice variant of the androgen receptor, AR-V7, confers resistance to AR-targeted therapies (ATTs) but not taxane chemotherapies in patients with metastatic castration-resistant prostate cancer. Since August 2015, a clinical-grade assay to detect AR-V7 messenger RNA expression in...

Cite
Markowski MC, Silberstein JL, Eshleman JR, et al. Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017;2017doi: 10.1200/PO.17.00127.
Markowski, M. C., Silberstein, J. L., Eshleman, J. R., Eisenberger, M. A., Luo, J., & Antonarakis, E. S. (2017). Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO precision oncology, 2017. https://doi.org/10.1200/PO.17.00127
Markowski, Mark C, et al. "Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer." JCO precision oncology vol. 2017 (2017). doi: https://doi.org/10.1200/PO.17.00127
Markowski MC, Silberstein JL, Eshleman JR, Eisenberger MA, Luo J, Antonarakis ES. Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00127. Epub 2017 Oct 30. PMID: 29170762; PMCID: PMC5697780.
Copy Download .nbib Format: NLM
Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy.

JCO precision oncology

Velho PI, Lim D, Wang H, Park JC, Kaur HB, Almutairi F, Carducci MA, Denmeade SR, Markowski MC, Isaacs WB, Antonarakis ES, Pritchard CC, Eisenberger MA, Lotan TL.
PMID: 31650100
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00081. Epub 2019 Jul 26.

PURPOSE: Very high-risk prostate cancer (PC) is associated with poor response to local and systemic treatments; however, few cases have been molecularly profiled. We studied clinical outcomes and molecular profiles of patients with clinically localized primary Gleason pattern 5...

Cite
Velho PI, Lim D, Wang H, et al. Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. JCO Precis Oncol. 2019;3doi: 10.1200/PO.19.00081.
Velho, P. I., Lim, D., Wang, H., Park, J. C., Kaur, H. B., Almutairi, F., Carducci, M. A., Denmeade, S. R., Markowski, M. C., Isaacs, W. B., Antonarakis, E. S., Pritchard, C. C., Eisenberger, M. A., & Lotan, T. L. (2019). Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. JCO precision oncology, 3. https://doi.org/10.1200/PO.19.00081
Velho, Pedro Isaacsson, et al. "Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy." JCO precision oncology vol. 3 (2019). doi: https://doi.org/10.1200/PO.19.00081
Velho PI, Lim D, Wang H, Park JC, Kaur HB, Almutairi F, Carducci MA, Denmeade SR, Markowski MC, Isaacs WB, Antonarakis ES, Pritchard CC, Eisenberger MA, Lotan TL. Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00081. Epub 2019 Jul 26. PMID: 31650100; PMCID: PMC6812513.
Copy Download .nbib Format: NLM
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.

European urology

Markowski MC, Wang H, Sullivan R, Rifkind I, Sinibaldi V, Schweizer MT, Teply BA, Ngomba N, Fu W, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Luo J, Antonarakis ES, Denmeade SR.
PMID: 32624280
Eur Urol. 2021 May;79(5):692-699. doi: 10.1016/j.eururo.2020.06.042. Epub 2020 Jul 02.

BACKGROUND: Cyclic high-dose testosterone injections, also known as bipolar androgen therapy (BAT), is a novel treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). BAT has shown clinical activity in prior studies enrolling men with mCRPC and may...

Cite
Markowski MC, Wang H, Sullivan R, et al. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. Eur Urol. 2020;79(5):692-699doi: 10.1016/j.eururo.2020.06.042.
Markowski, M. C., Wang, H., Sullivan, R., Rifkind, I., Sinibaldi, V., Schweizer, M. T., Teply, B. A., Ngomba, N., Fu, W., Carducci, M. A., Paller, C. J., Marshall, C. H., Eisenberger, M. A., Luo, J., Antonarakis, E. S., & Denmeade, S. R. (2021). A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European urology, 79(5), 692-699. https://doi.org/10.1016/j.eururo.2020.06.042
Markowski, Mark C, et al. "A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts." European urology vol. 79,5 (2021): 692-699. doi: https://doi.org/10.1016/j.eururo.2020.06.042
Markowski MC, Wang H, Sullivan R, Rifkind I, Sinibaldi V, Schweizer MT, Teply BA, Ngomba N, Fu W, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Luo J, Antonarakis ES, Denmeade SR. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. Eur Urol. 2021 May;79(5):692-699. doi: 10.1016/j.eururo.2020.06.042. Epub 2020 Jul 02. PMID: 32624280; PMCID: PMC7775877.
Copy Download .nbib Format: NLM
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.

European urology

Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, Kishan AU, Maurer T, Boutros PC, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng FY, Eisenberger M, Carducci M, Pienta KJ, Markowski M, Paller CJ, Antonarakis ES, Berlin A, Ost P, Tran PT.
PMID: 33419682
Eur Urol. 2021 Nov;80(5):632-640. doi: 10.1016/j.eururo.2020.12.040. Epub 2021 Jan 06.

BACKGROUND: Emerging data suggest that metastasis is a spectrum of disease burden rather than a binary state, and local therapies, such as radiation, might improve outcomes in oligometastasis. However, current definitions of oligometastasis are solely numerical.OBJECTIVE: To characterize the...

Cite
Deek MP, Van der Eecken K, Phillips R, et al. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. Eur Urol. 2021;80(5):632-640doi: 10.1016/j.eururo.2020.12.040.
Deek, M. P., Van der Eecken, K., Phillips, R., Parikh, N. R., Isaacsson Velho, P., Lotan, T. L., Kishan, A. U., Maurer, T., Boutros, P. C., Hovens, C., Abramowtiz, M., Pollack, A., Desai, N., Stish, B., Feng, F. Y., Eisenberger, M., Carducci, M., Pienta, K. J., Markowski, M., Paller, C. J., Antonarakis, E. S., Berlin, A., Ost, P., & Tran, P. T. (2021). The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European urology, 80(5), 632-640. https://doi.org/10.1016/j.eururo.2020.12.040
Deek, Matthew P, et al. "The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited." European urology vol. 80,5 (2021): 632-640. doi: https://doi.org/10.1016/j.eururo.2020.12.040
Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, Kishan AU, Maurer T, Boutros PC, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng FY, Eisenberger M, Carducci M, Pienta KJ, Markowski M, Paller CJ, Antonarakis ES, Berlin A, Ost P, Tran PT. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. Eur Urol. 2021 Nov;80(5):632-640. doi: 10.1016/j.eururo.2020.12.040. Epub 2021 Jan 06. PMID: 33419682.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 135 entries